Adial Pharmaceuticals, Inc. Finance Lease, Right-of-Use Asset, Amortization
Adial Pharmaceuticals, Inc. (ADIL) reported Finance Lease, Right-of-Use Asset, Amortization of $13.77 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-05-12
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2023-03-31 was $13.77K, a 8.93% increase year-over-year.
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2022-12-31 was $13.47K, a 8.79% increase year-over-year.
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2022-09-30 was $13.19K, a 8.65% increase year-over-year.
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2022-06-30 was $12.91K, a 8.51% increase year-over-year.
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $52.21K, a 8.58% increase from fiscal 2021.
- Adial Pharmaceuticals, Inc. finance lease, right-of-use asset, amortization for fiscal 2021 was $48.09K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2023-03-31 | $13.77K 10-Q · filed 2023-05-12 | $27.24K derived: sum of 2 quarters · filed 2023-05-12 | $40.43K derived: sum of 3 quarters · filed 2023-05-12 | $53.34K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $13.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $26.66K derived: sum of 2 quarters · filed 2023-03-30 | $39.57K derived: sum of 3 quarters · filed 2023-03-30 | $52.21K 10-K · filed 2023-03-30 |
| 2022-09-30 | $13.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $26.10K derived: sum of 2 quarters · filed 2022-11-14 | $38.74K 10-Q · filed 2022-11-14 | $51.12K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | $12.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $25.55K 10-Q · filed 2022-08-15 | $37.93K derived: sum of 3 quarters · filed 2023-05-12 | $50.07K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | $12.64K 10-Q · filed 2023-05-12 | $25.02K derived: sum of 2 quarters · filed 2023-05-12 | $37.16K derived: sum of 3 quarters · filed 2023-05-12 | $49.06K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $12.38K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $24.52K derived: sum of 2 quarters · filed 2023-03-30 | $36.42K derived: sum of 3 quarters · filed 2023-03-30 | $48.09K 10-K · filed 2023-03-30 |
| 2021-09-30 | $12.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $24.04K derived: sum of 2 quarters · filed 2022-11-14 | $35.70K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $11.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $23.56K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $11.66K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |